GeneDx (NASDAQ:WGS) Shares Up 8.6% on Insider Buying Activity

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) shot up 8.6% during mid-day trading on Tuesday following insider buying activity. The stock traded as high as $56.68 and last traded at $56.23. 829,324 shares changed hands during trading, a decline of 20% from the average session volume of 1,033,621 shares. The stock had previously closed at $51.80.

Specifically, Director Casdin Capital, Llc acquired 50,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were acquired at an average cost of $52.86 per share, with a total value of $2,643,000.00. Following the transaction, the director owned 3,707,164 shares in the company, valued at $195,960,689.04. The trade was a 1.37% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Casdin Capital, Llc acquired 150,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were purchased at an average cost of $56.44 per share, for a total transaction of $8,466,000.00. Following the completion of the transaction, the director owned 3,657,164 shares in the company, valued at approximately $206,410,336.16. This represents a 4.28% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Analyst Upgrades and Downgrades

Several analysts have weighed in on WGS shares. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research report on Monday, February 23rd. Zacks Research cut GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Piper Sandler reaffirmed an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Finally, Canaccord Genuity Group set a $75.00 price objective on GeneDx and gave the company a “buy” rating in a research report on Tuesday, May 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital made another large insider purchase, buying 50,000 shares at $52.86 after also buying 150,000 shares earlier in the week. Repeated insider accumulation can signal confidence in GeneDx’s long-term value. SEC filing
• Neutral Sentiment: Analyst coverage remains generally favorable, with GeneDx holding an average “Moderate Buy” rating, which may help support sentiment if fundamentals improve. Analyst rating update
• Negative Sentiment: Multiple law firms are promoting or reminding investors about a securities class-action lawsuit against GeneDx, creating a legal overhang and raising uncertainty around prior disclosures and shareholder losses. Class action announcement
• Negative Sentiment: The lawsuits focus on the sharp post-earnings selloff and alleged misstatements tied to the Fabric Genomics acquisition, keeping investor attention on execution and disclosure risk. Litigation article

GeneDx Price Performance

The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $1.66 billion, a PE ratio of -20.84 and a beta of 1.96. The firm has a 50 day moving average price of $55.25 and a 200 day moving average price of $92.12.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter last year, the company earned ($0.23) earnings per share. Research analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in GeneDx by 4.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after buying an additional 52,322 shares during the period. Vanguard Group Inc. boosted its holdings in shares of GeneDx by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock valued at $154,650,000 after purchasing an additional 18,647 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of GeneDx by 60.4% in the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock valued at $142,154,000 after acquiring an additional 411,607 shares during the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock valued at $132,435,000 after acquiring an additional 474,167 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of GeneDx by 59.2% in the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock valued at $102,288,000 after acquiring an additional 292,394 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.